First Participant Dosed in Phase 1/2 RLYB211 Trial for FNAIT

In a recent press release, biopharmaceutical company Rallybio announced that the first participant was dosed in a Phase 1/2 clinical trial. Currently, only healthy male participants are enrolled in the…

Continue Reading First Participant Dosed in Phase 1/2 RLYB211 Trial for FNAIT

New Investigative Therapy for Myelofibrosis Patients with Severe Thrombocytopenia is Making Headway

CTI BioPharma has just announced that they are submitting a NDA for Pacritinib as a new option for myelofibrosis patients who are facing severe thrombocytopenia. The thrombocytopenia is a result…

Continue Reading New Investigative Therapy for Myelofibrosis Patients with Severe Thrombocytopenia is Making Headway
Overview: Identifying and Managing 3 Scleroderma Emergencies
source: pixabay.com

Overview: Identifying and Managing 3 Scleroderma Emergencies

  Thanks to the rampant spread of COVID-19, many events, symposiums, and clinics moved online. One was the 2020 ACR State-of-the-Art Clinical Symposium, in which participants discuss diagnostic information, treatments,…

Continue Reading Overview: Identifying and Managing 3 Scleroderma Emergencies
Study: Felty’s Syndrome Presents Differently in Pediatric Patients
source: pixabay.com

Study: Felty’s Syndrome Presents Differently in Pediatric Patients

According to a study published in BMC Pediatrics, the rare disease known as Felty's syndrome is primarily known to affects adults between the ages of 50 and 70, but on very rare…

Continue Reading Study: Felty’s Syndrome Presents Differently in Pediatric Patients
Rivaroxaban Lowers Risk of Venous Thromboembolism for Orthopedic Surgeries as Compared to Heparin
source: pixabay.com

Rivaroxaban Lowers Risk of Venous Thromboembolism for Orthopedic Surgeries as Compared to Heparin

  According to a news release from the American College of Cardiology, rivaroxaban is more effective than enoxaprin (heparin) in preventing blood clots or low platelet counts in patients after…

Continue Reading Rivaroxaban Lowers Risk of Venous Thromboembolism for Orthopedic Surgeries as Compared to Heparin
ICYMI: A New Phase 3 Trial for Acute Myeloid Leukemia is Now Enrolling Patients
source: pixabay.com

ICYMI: A New Phase 3 Trial for Acute Myeloid Leukemia is Now Enrolling Patients

SELLAS has just announced that patient screening has begun for a Phase 3 trial for acute myeloid leukemia (AML). The trial is examining the effects of GPS for patients who…

Continue Reading ICYMI: A New Phase 3 Trial for Acute Myeloid Leukemia is Now Enrolling Patients
XPOVIO Being Evaluated for Treatment of Diffuse Large B-Cell Lymphoma
Source: https://pixabay.com/en/white-blood-cell-cell-blood-cell-543471/

XPOVIO Being Evaluated for Treatment of Diffuse Large B-Cell Lymphoma

Karyopharm, a pharmaceutical company based in Newton, Massachusetts, has submitted a New Drug Application to the FDA for their drug XPOVIO, which is meant for the treatment of diffuse large…

Continue Reading XPOVIO Being Evaluated for Treatment of Diffuse Large B-Cell Lymphoma
First Patient Dosed in Phase 2 Fanconi Anemia Clinical Trial
source: pixabay.com

First Patient Dosed in Phase 2 Fanconi Anemia Clinical Trial

According to a story from BioPortfolio, the drug developer Rocket Pharmaceuticals recently announced that the first patient has been dosed in the company's phase 2 clinical trial. This study is…

Continue Reading First Patient Dosed in Phase 2 Fanconi Anemia Clinical Trial
Experimental Treatment for Immune Thrombocytopenia Begins Trials in China
kalhh / Pixabay

Experimental Treatment for Immune Thrombocytopenia Begins Trials in China

According to a story from uk.finance.yahoo.com, the company Hutchison China MediTech Limited ("Chi-Med") has recently kicked off a phase 1 clinical trial. This trial is testing the company's investigational drug…

Continue Reading Experimental Treatment for Immune Thrombocytopenia Begins Trials in China
NIH Grants Funding for Scientist’s Heparin-Induced Thrombocytopenia Biomarker Research
source: pixabay.com

NIH Grants Funding for Scientist’s Heparin-Induced Thrombocytopenia Biomarker Research

According to a publication on EurekAlert, the National Institutes of Health recently awarded Dr. Jason Karnes, PharmD, PhD (and assistant professor in the University of Arizona College of Pharmacy) with…

Continue Reading NIH Grants Funding for Scientist’s Heparin-Induced Thrombocytopenia Biomarker Research
Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients
Source: Pixabay

Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients

Thanks to a Phase 2 trial, pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Ph+ ALL, now have a new treatment option. The FDA has announced approval of Sprycel…

Continue Reading Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients
Nplate Now Approved for Pediatric Patients with Immune Thrombocytopenia!
Source: Pixabay.com

Nplate Now Approved for Pediatric Patients with Immune Thrombocytopenia!

Immune Thrombocytopenia (ITP) is diagnosed by low platelet counts in the blood. It also causes impaired platelet production. This put patients at risk for serious bleeding as well as spontaneous bruising.…

Continue Reading Nplate Now Approved for Pediatric Patients with Immune Thrombocytopenia!
Study Finds That Immune Thrombocytopenia Patients Don’t See Eye to Eye on Fatigue
andibreit / Pixabay

Study Finds That Immune Thrombocytopenia Patients Don’t See Eye to Eye on Fatigue

According to a story from Oncology Nurse Advisor, a recent study found that patients with immune thrombocytopenia do not carry the same understanding as their doctors do when it comes…

Continue Reading Study Finds That Immune Thrombocytopenia Patients Don’t See Eye to Eye on Fatigue
Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy
frolicsomepl / Pixabay

Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy

According to a story from Market Screener, an analysis of real-world data (data gathered outside of the clinical setting) suggests that the drug eltrombopag, marketed as Revolade, offers substantial advantages…

Continue Reading Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy
Finally Severe Aplastic Anemia Patients will Have Access to Eltrombopag
Free-Photos / Pixabay

Finally Severe Aplastic Anemia Patients will Have Access to Eltrombopag

Eltrombopag (Promacta) has now been approved for all individuals in the US with severe aplastic anemia. The drug will be accessible to both pediatric and adult patients. This is huge news.…

Continue Reading Finally Severe Aplastic Anemia Patients will Have Access to Eltrombopag

Experimental Treatment For Small Cell Lung Cancer Receives Orphan Drug Designation

According to a story from pm360online.com, the drug development company Cytori Therapeutics recently announced that its investigational product ATI-1123 has been granted Orphan Drug designation from the US Food and…

Continue Reading Experimental Treatment For Small Cell Lung Cancer Receives Orphan Drug Designation
A Supplemental New Drug Application Has Been Submitted for a Potential Treatment of Immune Thrombocytopenia
jarmoluk / Pixabay

A Supplemental New Drug Application Has Been Submitted for a Potential Treatment of Immune Thrombocytopenia

Dova Pharmaceutics has submitted a supplemental New Drug Application to the US FDA on behalf of Doptelet® (avatrombopag), which is being researched as an investigational treatment of immune thrombocytopenia in…

Continue Reading A Supplemental New Drug Application Has Been Submitted for a Potential Treatment of Immune Thrombocytopenia
Close Menu